Statement of Changes in Beneficial Ownership (4)
September 03 2020 - 5:58PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
CRUTCHFIELD BRADFORD |
2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc.
[
TXG
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Commercial Officer |
(Last)
(First)
(Middle)
C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/1/2020 |
(Street)
PLEASANTON, CA 94588
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Class A Common Stock | 9/1/2020 | | M(1) | | 13776 | A | $1.16 | 14739 | D | |
Class A Common Stock | 9/1/2020 | | S(1) | | 2600 | D | $112.9204 (2) | 12139 | D | |
Class A Common Stock | 9/1/2020 | | S(1) | | 5887 | D | $113.8214 (3) | 6252 | D | |
Class A Common Stock | 9/1/2020 | | S(1) | | 4789 | D | $114.6459 (4) | 1463 | D | |
Class A Common Stock | 9/1/2020 | | S(1) | | 500 | D | $115.4088 (5) | 963 | D | |
Class A Common Stock | 9/2/2020 | | M(1) | | 3224 | A | $1.16 | 4187 | D | |
Class A Common Stock | 9/2/2020 | | S(1) | | 1000 | D | $111.3273 (6) | 3187 | D | |
Class A Common Stock | 9/2/2020 | | S(1) | | 1496 | D | $112.3226 (7) | 1691 | D | |
Class A Common Stock | 9/2/2020 | | S(1) | | 528 | D | $113.1799 (8) | 1163 | D | |
Class A Common Stock | 9/2/2020 | | S(1) | | 150 | D | $114.10 (9) | 1013 | D | |
Class A Common Stock | 9/2/2020 | | S(1) | | 50 | D | $114.89 | 963 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $1.16 | 9/1/2020 | | M (1) | | | 13776 | (10) | 2/3/2027 | Class A Common Stock | 13776 | $0.00 | 684224 | D | |
Stock Option (right to buy) | $1.16 | 9/2/2020 | | M (1) | | | 3224 | (11) | 2/3/2027 | Class A Common Stock | 3224 | $0.00 | 681000 | D | |
Explanation of Responses: |
(1) | The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. |
(2) | This transaction was executed in multiple trades at prices ranging from $112.25 to $113.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(3) | This transaction was executed in multiple trades at prices ranging from $113.26 to $114.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(4) | This transaction was executed in multiple trades at prices ranging from $114.27 to $115.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(5) | This transaction was executed in multiple trades at prices ranging from $115.29 to $115.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(6) | This transaction was executed in multiple trades at prices ranging from $110.79 to $111.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(7) | This transaction was executed in multiple trades at prices ranging from $111.80 to $112.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(8) | This transaction was executed in multiple trades at prices ranging from $112.82 to $113.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(9) | This transaction was executed in multiple trades at prices ranging from $113.82 to $114.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
(10) | This option, originally for 800,000 shares, of which 115,776 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
(11) | This option, originally for 800,000 shares, of which 119,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
CRUTCHFIELD BRADFORD C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON, CA 94588 |
|
| Chief Commercial Officer |
|
Signatures
|
/s/ Eric S. Whitaker, as Attorney-in-Fact | | 9/3/2020 |
**Signature of Reporting Person | Date |
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2023 to Apr 2024